<p><strong>Lakewood-Amedex Biotherapeutics Inc. (LABT)</strong> 的股票週一交易上漲，但隨後反轉並開始下跌，此前該公司公佈了 Nu-3 的數據。</p>
<ul>
<li>Lakewood-Amedex 股票正在測試關鍵支撐位。LABT 走弱的原因是什麼？</li>
</ul>
<h2>Lakewood-Amedex 強調 Nu-3 的製造進展</h2>
<p>Lakewood-Amedex 表示，Nu-3 正在開發為一種局部給藥的治療方法，旨在減少輕度感染的糖尿病足潰瘍的抗微生物耐藥風險。</p>
<p>該公司表示，已根據當前良好生產規範（cGMP）指南完成了多個多公斤規模的製造運行，效率很高。Lakewood-Amedex 還表示，工藝開發的進展改善了商品成本，並生產出具有增強物理化學特性的原料藥。</p>
<p>此外，該公司表示，Nu-3 膠體配方的多公斤數量已在 cGMP 指南下製造，適合用於臨牀試驗。</p>
<p>“Lakewood-Amedex Biotherapeutics (LABT) 一直在努力優化生產所需的配方和製造工藝，以生產 Bisphosphocin 藥物原料和藥品，” 首席執行官 <strong>Kelvin Cooper</strong> 説。</p>
<p>Cooper 表示，Bisphosphocin 類化合物可能適應多種藥物產品配方和給藥方法，包括在複雜尿路感染和肺部感染中的潛在應用。</p>
<p>該公司還宣佈，穩定性測試表明，Nu-3 原料藥材料在至少五年內保持穩定，而 Nu-3 藥品配方在至少兩年內保持穩定。</p>
<p>Lakewood-Amedex 表示，初步的生物負荷和抗微生物有效性測試顯示，在至少兩年內未檢測到生物負荷水平，並且產品不需要額外的防腐劑來維持抗微生物有效性。</p>
<p><strong>另請閲讀：今日股市：在阿聯酋核電站襲擊後，道瓊斯、標準普爾 500、納斯達克期貨下跌——Regeneron Pharma、NextNRG、ServiceNow 備受關注（更新）</strong></p>
<h2>Lakewood-Amedex 股票下跌</h2>
<p><strong>LABT 價格動態：</strong> 根據 Benzinga Pro 的數據，截至發佈時，Lakewood-Amedex 股票交易下跌 22.67%，報 $1.15。</p>
<p><em>圖片來源於 Shutterstock</em></p>

LABT

<p>Lakewood-Amedex Biotherapeutics Inc.（納斯達克代碼：LABT）股價下跌 22.67%，至 1.15 美元，儘管該公司宣佈了其針對糖尿病足潰瘍的 Nu-3 治療的積極生產更新。公司報告了成功的多公斤規模生產運行和穩定性測試結果，表明該產品的長期穩定性和有效性。然而，股價逆轉了早前的漲幅，目前正在測試關鍵支撐位</p>

<p><strong>Lakewood-Amedex Biotherapeutics Inc. ( LABT )</strong> shares were trading higher Monday but have since reversed and begun trading lower after the company announced data for Nu-3.</p>
<div class="lb-trans"><p><strong>Lakewood-Amedex Biotherapeutics Inc. (LABT)</strong> 的股票週一交易上漲，但隨後反轉並開始下跌，此前該公司公佈了 Nu-3 的數據。</p>
</div><ul>
<li>Lakewood-Amedex stock is testing key support levels. What’s behind LABT weakness?</li>
</ul>
<div class="lb-trans"><ul>
<li>Lakewood-Amedex 股票正在測試關鍵支撐位。LABT 走弱的原因是什麼？</li>
</ul>
</div><h2>Lakewood-Amedex Highlights Manufacturing Progress For Nu-3</h2>
<div class="lb-trans"><h2>Lakewood-Amedex 強調 Nu-3 的製造進展</h2>
</div><p>Lakewood-Amedex said Nu-3 is being developed as a topically delivered treatment for mildly infected diabetic foot ulcers designed to reduce the risk of antimicrobial resistance.</p>
<div class="lb-trans"><p>Lakewood-Amedex 表示，Nu-3 正在開發為一種局部給藥的治療方法，旨在減少輕度感染的糖尿病足潰瘍的抗微生物耐藥風險。</p>
</div><p>The company said it completed several multikilogram-scale manufacturing runs for members of its Bisphosphocin class of compounds under current Good Manufacturing Practices guidelines with high efficiency. Lakewood-Amedex also said process development advances improved cost of goods and produced bulk drug substance with enhanced physical chemistry characteristics.</p>
<div class="lb-trans"><p>該公司表示，已根據當前良好生產規範（cGMP）指南完成了多個多公斤規模的製造運行，效率很高。Lakewood-Amedex 還表示，工藝開發的進展改善了商品成本，並生產出具有增強物理化學特性的原料藥。</p>
</div><p>In addition, the company said multikilogram quantities of the Nu-3 gel formulation have been manufactured under cGMP guidelines and are suitable for use in clinical trials.</p>
<div class="lb-trans"><p>此外，該公司表示，Nu-3 膠體配方的多公斤數量已在 cGMP 指南下製造，適合用於臨牀試驗。</p>
</div><p>&#34;Lakewood-Amedex Biotherapeutics ( LABT ) has worked diligently to optimize formulation and manufacturing processes required to produce both the Bisphosphocin drug substances and drug products,&#34; said CEO <strong>Kelvin Cooper</strong>.</p>
<div class="lb-trans"><p>“Lakewood-Amedex Biotherapeutics (LABT) 一直在努力優化生產所需的配方和製造工藝，以生產 Bisphosphocin 藥物原料和藥品，” 首席執行官 <strong>Kelvin Cooper</strong> 説。</p>
</div><p>Cooper said the Bisphosphocin class of compounds could potentially be adapted to a range of drug product formulations and delivery methods, including possible applications in complicated urinary tract infections and pulmonary infections.</p>
<div class="lb-trans"><p>Cooper 表示，Bisphosphocin 類化合物可能適應多種藥物產品配方和給藥方法，包括在複雜尿路感染和肺部感染中的潛在應用。</p>
</div><p>The company also announced that stability testing showed the Nu-3 bulk drug substance material remained stable for at least five years, while the Nu-3 drug product formulation remained stable for at least two years.</p>
<div class="lb-trans"><p>該公司還宣佈，穩定性測試表明，Nu-3 原料藥材料在至少五年內保持穩定，而 Nu-3 藥品配方在至少兩年內保持穩定。</p>
</div><p>Lakewood-Amedex said initial testing for bioburden and antimicrobial effectiveness demonstrated undetectable bioburden levels for at least two years and showed the product does not require additional preservatives to maintain antimicrobial effectiveness.</p>
<div class="lb-trans"><p>Lakewood-Amedex 表示，初步的生物負荷和抗微生物有效性測試顯示，在至少兩年內未檢測到生物負荷水平，並且產品不需要額外的防腐劑來維持抗微生物有效性。</p>
</div><p><strong>Read Also: Stock Market Today: Dow, S&amp;P 500, Nasdaq Futures Drop After UAE Nuclear Plant Strike— Regeneron Pharma, NextNRG, ServiceNow In Focus (UPDATED)</strong></p>
<div class="lb-trans"><p><strong>另請閲讀：今日股市：在阿聯酋核電站襲擊後，道瓊斯、標準普爾 500、納斯達克期貨下跌——Regeneron Pharma、NextNRG、ServiceNow 備受關注（更新）</strong></p>
</div><h2>Lakewood-Amedex Shares Fall</h2>
<div class="lb-trans"><h2>Lakewood-Amedex 股票下跌</h2>
</div><p><strong>LABT Price Action:</strong> At the time of publication, Lakewood-Amedex shares are trading 22.67% lower at $1.15, according to data from Benzinga Pro.</p>
<div class="lb-trans"><p><strong>LABT 價格動態：</strong> 根據 Benzinga Pro 的數據，截至發佈時，Lakewood-Amedex 股票交易下跌 22.67%，報 $1.15。</p>
</div><p><em>Image via Shutterstock</em></p>
<div class="lb-trans"><p><em>圖片來源於 Shutterstock</em></p>
</div>

儘管 Nu-3 製造更新積極，Lakewood-Amedex 的股票仍然下跌